Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Plasma dexamethasone concentrations and the dexamethasone suppression test.

J C Ritchie1, B M Belkin, K R Krishnan

  • 1Department of Psychiatry, Duke University, Durham, NC 27710.

Biological Psychiatry
|January 15, 1990
PubMed
Summary

Altered dexamethasone (dex) bioavailability or pharmacokinetics may affect Dexamethasone Suppression Test (DST) results in psychiatric patients. Lower plasma dex levels were observed in DST nonsuppressors, suggesting these factors influence test outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A proof of concept case series of botulinum toxin a treatment for ischemic feet due to Raynaud's phenomenon.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2026
Same author

Sulodexide in venous disease.

Journal of thrombosis and haemostasis : JTH·2018
Same author

A genome-wide association study of antidepressant response in Koreans.

Translational psychiatry·2015
Same author

Clinical science and biomarkers: against RDoC.

Acta psychiatrica Scandinavica·2015
Same author

A genome-wide association study of antidepressant response in Koreans.

Translational psychiatry·2015
Same author

Association of the choline acetyltransferase gene with responsiveness to acetylcholinesterase inhibitors in Alzheimer's disease.

Pharmacopsychiatry·2015

Area of Science:

  • Neuroscience
  • Endocrinology
  • Psychiatry

Background:

  • The Dexamethasone Suppression Test (DST) is used to assess hypothalamic-pituitary-adrenal (HPA) axis function in psychiatric disorders.
  • Altered pharmacokinetics or bioavailability of dexamethasone (dex) may confound DST results, particularly in patients with major depressive disorder (MDD).
  • Accurate interpretation of the DST relies on understanding factors that influence dexamethasone levels and cortisol suppression.

Purpose of the Study:

  • To investigate the relationship between plasma dexamethasone concentrations, plasma cortisol levels, and Dexamethasone Suppression Test (DST) results in psychiatric patients.
  • To evaluate the potential contribution of altered dexamethasone bioavailability or pharmacokinetics to DST outcomes.
  • To validate a fluorescent polarization immunoassay (FPIA) for cortisol measurement in DST.

Related Experiment Videos

Main Methods:

  • Plasma dexamethasone and cortisol concentrations were measured in 32 MDD patients, 14 other psychiatric patients, and 16 healthy controls.
  • Cortisol was measured using competitive protein binding (CPB) assay and fluorescent polarization immunoassay (FPIA).
  • Dexamethasone was measured using radioimmunoassay (RIA).

Main Results:

  • Agreement between FPIA and CPB cortisol assays was excellent.
  • DST nonsuppressors exhibited significantly higher mean plasma cortisol concentrations compared to suppressors across multiple time points post-dexamethasone administration.
  • Plasma dexamethasone concentrations were significantly lower in DST nonsuppressors compared to suppressors, irrespective of diagnostic group.

Conclusions:

  • Altered dexamethasone bioavailability or pharmacokinetics may significantly contribute to DST results in psychiatric patients.
  • Lower plasma dexamethasone levels in nonsuppressors suggest impaired absorption or altered metabolism.
  • Further research is needed to explore the role of dexamethasone quantification and metabolite analysis in enhancing DST interpretability.